EA201691525A1 - Применение кладрибина для лечения оптиконевромиелита - Google Patents

Применение кладрибина для лечения оптиконевромиелита

Info

Publication number
EA201691525A1
EA201691525A1 EA201691525A EA201691525A EA201691525A1 EA 201691525 A1 EA201691525 A1 EA 201691525A1 EA 201691525 A EA201691525 A EA 201691525A EA 201691525 A EA201691525 A EA 201691525A EA 201691525 A1 EA201691525 A1 EA 201691525A1
Authority
EA
Eurasian Patent Office
Prior art keywords
igg
nmo
hereinafter referred
mri
opticonevromyelitis
Prior art date
Application number
EA201691525A
Other languages
English (en)
Other versions
EA031244B1 (ru
Inventor
Артюр Энри Роа
Конрад Рейдак
Original Assignee
Корд Терапьютикс С.А.Р.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50287713&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201691525(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Корд Терапьютикс С.А.Р.Л. filed Critical Корд Терапьютикс С.А.Р.Л.
Publication of EA201691525A1 publication Critical patent/EA201691525A1/ru
Publication of EA031244B1 publication Critical patent/EA031244B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)

Abstract

2-Хлор-2'-дезоксиаденозин, в дальнейшем называемый кладрибином, или его фармацевтически приемлемая соль могут применяться в лечении или уменьшении тяжести оптиконевромиелита, в дальнейшем называемого OHM, например, у больных с подтвержденным определением NMO-IgG в сыворотке или у больных с подтвержденным невритом зрительного нерва, миелитом и по меньшей мере двумя из подтверждения по результатам МРТ сплошного поражения 3 или более сегментов спинного мозга, начала изменений на МРТ мозга, недиагностических в отношении рассеянного склероза, или определения NMO-IgG в сыворотке.
EA201691525A 2014-01-29 2015-01-27 Применение кладрибина для лечения оптиконевромиелита EA031244B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1401465.8A GB201401465D0 (en) 2014-01-29 2014-01-29 Use of cladribine for treating autoimmune inflammatory disease
PCT/GB2015/050177 WO2015114315A1 (en) 2014-01-29 2015-01-27 Use of cladribine for treating neuromyelitis optica

Publications (2)

Publication Number Publication Date
EA201691525A1 true EA201691525A1 (ru) 2016-12-30
EA031244B1 EA031244B1 (ru) 2018-12-28

Family

ID=50287713

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691525A EA031244B1 (ru) 2014-01-29 2015-01-27 Применение кладрибина для лечения оптиконевромиелита

Country Status (19)

Country Link
US (1) US10350231B2 (ru)
EP (1) EP3099307B2 (ru)
JP (1) JP6535678B2 (ru)
AU (1) AU2015212613B2 (ru)
CA (1) CA2937978C (ru)
CY (1) CY1120139T1 (ru)
DK (1) DK3099307T3 (ru)
EA (1) EA031244B1 (ru)
ES (1) ES2655291T5 (ru)
GB (1) GB201401465D0 (ru)
HR (1) HRP20180071T4 (ru)
HU (1) HUE036120T2 (ru)
LT (1) LT3099307T (ru)
NO (1) NO3099307T3 (ru)
PL (1) PL3099307T5 (ru)
PT (1) PT3099307T (ru)
RS (1) RS56727B2 (ru)
SI (1) SI3099307T2 (ru)
WO (1) WO2015114315A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109963570A (zh) 2017-01-21 2019-07-02 宁波知明生物科技有限公司 芍药苷-6’-o-苯磺酸酯在治疗干燥综合征的应用
EP3628310A1 (en) * 2018-09-25 2020-04-01 Synbias Pharma AG Pharmaceutical composition comprising solid dispersions of amorphous cladribine and pharmaceutically acceptable water soluble carrier
KR20220004113A (ko) * 2019-04-24 2022-01-11 비엘라 바이오, 인크. 자가면역 질환을 치료하기 위한 항-cd19 항체의 용도
CA3197022A1 (en) * 2020-10-29 2022-05-05 Dewei SHE Use of an anti-cd19 antibody to treat autoimmune disease
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease
WO2023242285A1 (en) 2022-06-15 2023-12-21 Vektor Pharma Tf Gmbh Sublingual formulation of anticancer compound for use in the treatment of autoimmune neurodegenerative diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
JP5412709B2 (ja) 2003-03-28 2014-02-12 アレス トレーディング ソシエテ アノニム 改良された経口及び経粘膜デリバリーのためのクラドリビン製剤
JP5795456B2 (ja) 2004-12-22 2015-10-14 メルク セローノ ソシエテ アノニム 多発性硬化症を治療するためのクラドリビン投薬計画
RS63489B1 (sr) 2007-02-08 2022-09-30 Biogen Ma Inc Kompozicije i upotrebe za tretiranje multiple skleroze
JP2011503035A (ja) 2007-11-12 2011-01-27 アレス トレーディング ソシエテ アノニム 視神経炎治療のためのｔａｃｉ−免疫グロブリン融合タンパク質
US9891219B2 (en) * 2008-10-10 2018-02-13 Mayo Foundation For Medical Education And Research Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
PL2477656T3 (pl) * 2009-09-15 2017-09-29 Csl Limited Leczenie stanów neurologicznych
EP2343075A1 (en) * 2010-01-04 2011-07-13 Neurotec Pharma, S.L. Diazoxide for use in the treatment a central nervous system (CNS) autoimmune demyelinating disease

Also Published As

Publication number Publication date
PT3099307T (pt) 2018-01-08
JP6535678B2 (ja) 2019-06-26
GB201401465D0 (en) 2014-03-12
ES2655291T5 (es) 2021-05-06
EA031244B1 (ru) 2018-12-28
SI3099307T2 (sl) 2020-11-30
AU2015212613A1 (en) 2016-09-01
NO3099307T3 (ru) 2018-03-17
HRP20180071T4 (hr) 2020-10-16
CY1120139T1 (el) 2018-12-12
PL3099307T5 (pl) 2020-11-30
US10350231B2 (en) 2019-07-16
EP3099307B1 (en) 2017-10-18
JP2017504636A (ja) 2017-02-09
RS56727B2 (sr) 2020-11-30
LT3099307T (lt) 2018-02-12
PL3099307T3 (pl) 2018-03-30
DK3099307T3 (en) 2018-01-22
HRP20180071T1 (hr) 2018-02-23
ES2655291T3 (es) 2018-02-19
WO2015114315A1 (en) 2015-08-06
RS56727B1 (sr) 2018-03-30
EP3099307B2 (en) 2020-07-29
US20160339049A1 (en) 2016-11-24
SI3099307T1 (en) 2018-02-28
EP3099307A1 (en) 2016-12-07
AU2015212613B2 (en) 2020-03-05
CA2937978A1 (en) 2015-08-06
CA2937978C (en) 2022-08-16
HUE036120T2 (hu) 2018-06-28

Similar Documents

Publication Publication Date Title
EA201691525A1 (ru) Применение кладрибина для лечения оптиконевромиелита
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
BR112017016952A2 (pt) terapia de combinação com fatores de coagulação e anticorpos multiespecíficos
PH12015502773A1 (en) Methods for treating or preventing opthalmological conditions
EA201891152A1 (ru) Экстрацеллюлярные везикулы нервных клеток
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
MX2015002289A (es) Anticuerpos humanos para gfr alfa 3 y métodos para su uso.
BR112017002637A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
GB2548942A (en) Protein biomarkers for acute, subacute and chronic traumatic injuries of the central nervous system
GEP20186927B (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
MX2015015907A (es) Metodo no invasivo objetivo para cuantificar el grado de comezon mediante el uso de mediciones psicofisiologicas.
MX2017000094A (es) PRODUCTOS INMUNOGENICOS BASADOS EN SECUENCIAS DE AMINOACIDOS DE MUTEINA AMILOIDE ß (Aß) Y USOS DE LOS MISMOS.
EA201790563A1 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
EA201492102A1 (ru) Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
EA201691567A1 (ru) Способы лечения легких травм головного мозга
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
PH12017501290A1 (en) Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide
WO2016042561A3 (en) Downregulating mir-132 for the treatment of lipid related disorders
TW201613583A (en) Laquinimod for the treatment of relapsing- remitting multiple sclerosis (RRMS) patients with a high disability status
PH12017501304A1 (en) Levodopa and carbidopa intestinal gel and method of use
PH12015502687A1 (en) Marker for acid sphingomyelinase disorders and uses thereof
BR112019002355A2 (pt) composições e métodos para prevenção de acidente vascular cerebral em pacientes pediátricos com anemia falciforme
MX2017006491A (es) Composiciones y métodos para la modulación de la actividad at2r.